Investigate the Clinical Responses of Ethosuximide in Patients With Treatment-Resistant Depression.

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

May 21, 2019

Primary Completion Date

April 1, 2021

Study Completion Date

April 1, 2021

Conditions
Depressive Disorder, Treatment-Resistant
Interventions
DRUG

Ethosuximide

2 times/day, take it orally after breakfast/dinner; take 500mg in the morning and 500mg in the evening on day1, 500mg in the morning and 750mg in the evening on day2, 750mg in the morning and 750mg in the evening on day3, 750mg in the morning and 1000mg in the evening on day4, 1000mg in the morning and 1000mg in the evening on day5, maintain this dose until the end of treatment for 2 weeks.

DRUG

Placebo

2 times/day, take it orally after breakfast/dinner; take 500mg in the morning and 500mg in the evening on day1, 500mg in the morning and 750mg in the evening on day2, 750mg in the morning and 750mg in the evening on day3, 750mg in the morning and 1000mg in the evening on day4, 1000mg in the morning and 1000mg in the evening on day5, maintain this dose until the end of treatment for 2 weeks.

DRUG

Escitalopram

1 time/day, 20mg/day, take it orally after breakfast, take it for 4 weeks without interruption.

Trial Locations (1)

310003

Department of Psychiatry, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou

All Listed Sponsors
lead

Zhejiang University

OTHER

NCT03887624 - Investigate the Clinical Responses of Ethosuximide in Patients With Treatment-Resistant Depression. | Biotech Hunter | Biotech Hunter